Search
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalIt is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine
Uric acid
go.drugbank.com/drugs/DB08844InvestigationalAs a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. … In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke.
Categories: Compounds used in a research, industrial, or household settingGuvacine
go.drugbank.com/drugs/DB08848ExperimentalGuvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.
Leukotriene C4
go.drugbank.com/drugs/DB08855ExperimentalThe conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produ...
Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine, L-γ-glutamyl-S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl]-L-cysteinylglycineCategories: SRS-ABamet-UD2
go.drugbank.com/drugs/DB08857ExperimentalBamet-UD2 is a novel bile acid-platinum derivative.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalIn January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. … [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[L11575] Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. … [A190492] Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalBelimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.
Rhamnose
go.drugbank.com/drugs/DB02961InvestigationalA methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Synonyms: L-rhamnose